| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441540 | European Journal of Cancer | 2016 | 9 Pages |
Abstract
Neither hypertension nor any blood pressure elevation above baseline was associated with efficacy outcomes of pazopanib or sunitinib. Accordingly, management of tyrosine kinase inhibitor-induced hypertension is unlikely to compromise outcome.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
David Goldstein, Jonathan E. Rosenberg, Robert A. Figlin, Raymond R. Townsend, Lauren McCann, Christopher Carpenter, Lini Pandite,